All In MedTech

FDA Clearance Tracker · P910018-S002

LIPOSORBER LA-15 SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 9, 2002 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P910018-S002
Device name
LIPOSORBER LA-15 SYSTEM
Applicant location
New York, NY
Received
Dec 15, 1998
Decided
Apr 9, 2002
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Postapproval Study Protocol
Original approval
P910018

Device type

Device class
Class III

Every decision under product code MMY

FDA's approval statement

As written in FDA's record.

APPROVAL FOR MODIFICATIONS TO THE PATIENT REGISTRY/POST-MARKET STUDY OF THE LIPOSORBER. LA-15 SYSTEM.

Source documents

Other decisions for Kaneka Pharma America Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.